Connect with us

Featured

Criptalia finances SMEs through Blockchain and Smart Contract

Criptalia implements the raising of capital through public blockchain protocols and security tokens that make investments safe and transparent without requiring any banking intermediation. Plus Biomedicals raised the necessary funds to produce Cwash, a patented device that allows people with disabilities to provide their oral hygiene without the use of water and toothpaste.

Published

on

This picture show a woman holding some euro bills.

Thanks to public blockchain protocols and security tokens applied to the raising of capital, new opportunities are opening up for SMEs in the Italian entrepreneurial fabric that will be able to access secure and efficient sources of financing in a very short time. The Brescia-based startup company Plus Biomedicals, in full lockdown, has managed to obtain a loan of $46,300 (€40,000) for the production of a mask for the oral hygiene of the disabled.

Find out more about Criptalia’s regulated digital platform for crowd-lending and be the first to read the most important business news of the moment with the Born2Invest mobile app.

Criptalia uses public blockchain protocols to implement the raising of capital

Criptalia was created in 2018 in Bergamo with the aim of providing support for economic financing to SMEs investing in growth projects with a direct impact on the real economy. The company offers a regulated digital platform for crowd-lending financing, the largest slice of the entire fintech lending sector, with a value of $796 million of transactions in 2020 in Italy, in third place after England and Switzerland.

In this way, companies obtain traditional loans, equity loans and bonds (including mini-bonds), in a very short time from private and institutional entities, bypassing the guarantees required by traditional banking and financial institutions. Private individuals, professional investors, savers, and institutional funds have the opportunity to finance entrepreneurial initiatives that have a positive impact on the real economy, without any cost or commission, with a good interest rate and low risk.

In addition, Criptalia implements the raising of capital through public blockchain protocols and security tokens that make investments safe and transparent without requiring any banking intermediation. Furthermore, they break down all barriers to access to credit by almost completely shortening the traditional process and reducing the number of actors in order to reduce time and costs.

SEE ALSO  Usain Bolt's shock defeat at his final race didn't diminish his greatness as the fastest man alive

Diego Dal Cero, CEO of Criptalia added: “Especially at a time like this, when the possibility of access to credit is becoming increasingly crucial to support the restart, it is important to rely on user-friendly, efficient and effective tools to obtain money in a very short time. Through our platform, we give SMEs an opportunity to grow quickly but, at the same time, we offer a good return to investors who choose to allocate a slice of their capital to projects in the Criptalia marketplace. In addition, we carefully select applications for funding by publishing only projects that have a positive impact in terms of economic development, employment and sustainability.”

Plus Biomedicals, the first startup financed with crowdlending

It is thanks to Criptalia that the project of Plus Biomedicals, a Brescia-based biotech startup founded by two young graduate engineers, will soon become a reality with a participatory loan of $46.300 (€40,000) that will designate the production of Cwash, a patented device (an automated mask) that allows people with disabilities to provide their oral hygiene without the use of water and toothpaste. 

The 44 people who have contributed with variable amounts depending on their availability, will receive an interest rate of 9% per year, made possible also thanks to the time and cost savings that the Criptalia platform is able to offer to companies and investors.

__

(Featured image by Tumisu via Pixabay)

DISCLAIMER: This article was written by a third party contributor and does not reflect the opinion of Born2Invest, its management, staff or its associates. Please review our disclaimer for more information.

This article may include forward-looking statements. These forward-looking statements generally are identified by the words “believe,” “project,” “estimate,” “become,” “plan,” “will,” and similar expressions. These forward-looking statements involve known and unknown risks as well as uncertainties, including those discussed in the following cautionary statements and elsewhere in this article and on this site. Although the Company may believe that its expectations are based on reasonable assumptions, the actual results that the Company may achieve may differ materially from any forward-looking statements, which reflect the opinions of the management of the Company only as of the date hereof. Additionally, please make sure to read these important disclosures.

First published in BLOCKCHAIN4INNOVATION, a third-party contributor translated and adapted the article from the original. In case of discrepancy, the original will prevail.

Although we made reasonable efforts to provide accurate translations, some parts may be incorrect. Born2Invest assumes no responsibility for errors, omissions or ambiguities in the translations provided on this website. Any person or entity relying on translated content does so at their own risk. Born2Invest is not responsible for losses caused by such reliance on the accuracy or reliability of translated information. If you wish to report an error or inaccuracy in the translation, we encourage you to contact us.

Olivia McCall is passionate about education, women and children’s rights, and the environment. A long-time investor, she covers news about the latest stocks (lately marijuana and tech), IPOs and indices, and is always on the lookout for socially responsible startups. She also writes about the food sector, and has a keen interest on cryptocurrencies.